What was recalled
If you or someone in your household takes medication for the management of parathyroid hormone levels, specifically Cinacalcet Hydrochloride Tablets at a dosage of 30 mg, it is important to verify whether your current supply is part of a recent safety notice. The U.S. Food and Drug Administration (FDA) has identified a specific batch of this prescription drug that requires immediate attention due to manufacturing inconsistencies. This recall involves products manufactured by Cipla Ltd., located in the MIDC area of Patalganga, India, but distributed under the brand name Cipla USA, Inc., which is headquartered at 10 Independence Boulevard, Suite 300, Warren, NJ 07059.
The specific items affected are Cinacalcet Hydrochloride Tablets packaged in 30-count bottles. These are strictly prescription-only medications, meaning they are not available over the counter and are typically dispensed through licensed pharmacies based on a doctor’s order. The recall targets two distinct groups of lot numbers, each with its own expiration timeline. The first group includes lots numbered 5PB0465, 5PB0466, and 5PB0557, all of which are set to expire on April 30, 2027. The second group consists of lots 5PB0629, 5PB0630, 5PB0633, 5PB0637, and 5PB0638, with a later expiration date of June 30, 2027.
To help you identify if your medication is part of this recall, look closely at the bottle label for the National Drug Code (NDC), which is listed as 69097-410-02. This unique identifier is crucial for confirming the exact product line involved. The distribution pattern for these recalled units was nationwide across the United States, with specific documentation noting the state of New Jersey in the official record. The recall was initiated on June 29, 2026, and is classified as a Class II recall by the FDA.
A Class II classification indicates that while the use of this product might cause temporary health problems or pose a slight threat of a serious nature, it is not expected to cause serious adverse health consequences. However, because these tablets contain deviations from current Good Manufacturing Practice (cGMP) standards—specifically regarding the presence of N-nitroso-cinacalcet above acceptable daily intake limits—the manufacturer and the FDA have deemed it necessary to pull these specific lots from the market to ensure patient safety. If you have any of the lot numbers listed above, please check your pharmacy records or the physical bottle immediately.
The hazard, explained
When you look at a medication bottle, you expect the contents to be exactly what the label promises: pure, safe, and effective. In this specific recall involving Cinacalcet Hydrochloride Tablets manufactured by Cipla Ltd., that expectation has been compromised due to significant deviations from Current Good Manufacturing Practices (cGMP). These are the rigorous, non-negotiable standards set by the FDA to ensure every pill produced meets strict quality criteria. The core issue here is chemical contamination. Specifically, testing revealed the presence of N-nitroso-cinacalcet, an unwanted impurity that should not be in the final product above a certain threshold.
To understand why this matters, we need to look at what N-nitroso compounds are. These are a class of chemicals that can form under specific conditions during manufacturing or storage, often when nitrogen-containing substances react with nitrites. The FDA has established an Acceptable Daily Intake (ADI) for such impurities. Think of the ADI as a safety buffer—a calculated limit representing the maximum amount of this impurity a person could consume every day over their lifetime without expecting any significant health risk. In this case, the contaminated batches contain levels of N-nitroso-cinacalcet that exceed this acceptable daily intake.
You might wonder, "If it’s just an impurity, how dangerous is it really?" The concern with nitrosamines like N-nitroso-cinacalcet is not necessarily acute toxicity from a single dose, but rather long-term cumulative risk. These compounds are widely recognized in the scientific community as potential carcinogens, meaning they have the potential to cause cancer after prolonged exposure. While the immediate physical effect of taking one pill might be unnoticeable, the mechanism of harm lies in the cellular level. Over time, if a patient continues to take medication with impurity levels above the safe limit, their body is exposed to a higher burden of these potentially damaging molecules than intended. This exceeds the safety margin that regulators and manufacturers design into the drug.
This is why the FDA has classified this as a Class II recall. A Class II designation indicates that use of or exposure to the defective product may cause temporary, medically reversible, or serious adverse health consequences, or where the probability of serious adverse health consequences is remote. In this context, the "remote" probability refers to the statistical likelihood of cancer developing from such exposure, but the potential consequence is severe enough to warrant a nationwide recall. The hazard isn't that the drug stops working; it's that it introduces an unquantified, unnecessary risk into your long-term health profile. By removing these specific lots from circulation, the goal is to eliminate that hidden variable entirely, ensuring that patients relying on Cinacalcet for conditions like hyperparathyroidism do so without the added burden of excessive impurity exposure.
Who is most at risk
To understand who is truly vulnerable in this recall, we first need to look at the nature of the medication itself. Cinacalcet Hydrochloride is not a common over-the-counter supplement or a drug used for minor ailments like headaches or colds. It is a prescription-only medication specifically designed to treat hyperparathyroidism, a condition where the parathyroid glands produce too much parathyroid hormone (PTH). This hormone imbalance can lead to dangerously high levels of calcium in the blood (hypercalcemia), which can cause kidney stones, bone pain, and other serious complications. Because this drug requires a prescription and is managed by specialists—typically endocrinologists or nephrologists—it is used by a relatively small, specialized group of patients rather than the general public. This specificity helps narrow the scope of concern significantly.
The primary group at risk consists of individuals who have been prescribed this specific medication to manage their calcium levels. According to the recall details, the affected product is a 30 mg strength tablet. Patients taking this exact dosage are the ones who need to check their bottles immediately. The recall affects multiple lot numbers manufactured by Cipla Ltd. in India and distributed nationwide by Cipla USA, Inc. If you have been diagnosed with hyperparathyroidism and your doctor has prescribed Cinacalcet Hydrochloride 30 mg, you are the direct audience for this alert. However, not all patients taking Cinacalcet are at risk from this specific recall; only those with the specific lot numbers listed in the FDA notice are affected.
Within this patient group, certain individuals may face heightened vulnerability due to how the hazard interacts with their physiology. The hazard here involves the presence of N-nitroso-cinacalcet, a contaminant that exceeds the acceptable daily intake (ADI) limits set by safety standards. While the recall is classified as Class II—meaning it is unlikely to cause serious adverse health consequences or death—it still represents a significant deviation from current Good Manufacturing Practices (cGMP). For patients with compromised kidney function, which is often comorbid with hyperparathyroidism, the body’s ability to filter and eliminate toxins can be reduced. Although N-nitroso compounds are generally concerning due to potential long-term risks, the immediate risk for most users in this specific recall is lower because the levels, while above the ADI, are not necessarily at acute toxic thresholds. Still, prolonged exposure for anyone is undesirable.
Elderly patients may be particularly cautious with this situation. Many individuals managing hyperparathyroidism are older adults who may also be taking multiple other medications for conditions like hypertension or diabetes. The presence of an unexpected contaminant in one of their pills adds an unnecessary layer of complexity to their already intricate medication regimen. For these patients, the "risk" is not just about the chemical itself, but also about the disruption it causes to their stable health routine. Sudden changes in medication supply can lead to gaps in treatment, which for hyperparathyroidism can result in rapid calcium spikes that are dangerous regardless of the contaminant. Therefore, the most at-risk individuals are those who rely on this specific prescription for daily management of a chronic condition and may have difficulty quickly obtaining a clean replacement.
It is also important to note that children are not typically the primary demographic for Cinacalcet Hydrochloride 30 mg tablets. This drug is generally prescribed for adults. However, if any pediatric patient has been prescribed this specific formulation off-label or under special circumstances, they should be included in the check. The risk profile for children would differ due to their lower body weight, meaning even small amounts of contaminants could have a proportionally larger impact. But given the adult-focused distribution pattern and typical prescribing practices, the vast majority of those affected will be adults managing chronic kidney disease or hyperparathyroidism.
In summary, the people most at risk are current users of Cinacalcet Hydrochloride 30 mg tablets from the specific lots listed in the FDA recall. They are vulnerable not necessarily because the contaminant is immediately lethal, but because they depend on this precise medication to control a serious hormonal imbalance. The disruption to their care, combined with the unknown long-term effects of exceeding acceptable intake levels for N-nitroso compounds, makes prompt action essential. If you are in this group, your risk is managed not by panic, but by verifying your lot number and contacting your pharmacist or doctor to replace the medication safely.
How to tell if you have the recalled item
Identifying whether your medication is part of this specific recall requires careful attention to several precise details on your prescription bottle. Because the FDA classifies this as a Class II recall, it is essential that patients and healthcare providers verify the exact product specifications before taking any action. The recall issued by Cipla USA, Inc. involves Cinacalcet Hydrochloride Tablets, specifically the 30 mg strength packaged in 30-count bottles. If your prescription is for a different dosage, such as 18 mg or 90 mg, or if it comes in a different package size, it is likely not affected by this particular notice, but you should always confirm with your pharmacist to be absolutely sure.
The most critical step is to locate the National Drug Code (NDC) printed on the label. You must look for NDC 69097-410-02. This unique identifier is assigned to this specific product manufactured by Cipla Ltd. in MIDC, Patalganga, India, and distributed by Cipla USA, Inc. in Warren, NJ. If the NDC on your bottle does not match this sequence exactly, the product is not part of this recall. Additionally, verify that the label indicates the product is "Rx Only" and lists Cipla as the manufacturer. The presence of these specific branding and manufacturing details helps distinguish the recalled items from other legitimate versions of Cinacalcet produced by different companies or under different licensing agreements.
Even if the NDC matches, you must check the lot numbers to determine if your specific bottles are implicated in this safety alert. The recall affects two distinct groups of expiration dates and their corresponding lot codes. First, look for lots with an expiration date of April 30, 2027 (Exp 4/30/2027). If your bottle expires on this date, check if the lot number is one of the following: 5PB0465, 5PB0466, or 5PB0557. Second, look for lots with an expiration date of June 30, 2027 (Exp 6/30/2027). If your bottle expires on this later date, verify if the lot number is 5PB0629, 5PB0630, 5PB0633, 5PB0637, or 5PB0638. Only bottles falling into these specific lot-and-expiration combinations are subject to this recall.
If you have a pharmacy receipt or an online order confirmation, cross-reference the printed label details with your documentation. The distribution pattern for this recall is nationwide across the United States, so the location where you purchased the medication does not limit its potential presence in your home. However, knowing that it was distributed nationally confirms that patients from any state could potentially have these items. Take a moment to physically inspect the bottle cap and side label for the NDC and lot numbers, as these are often small but vital for accurate identification. If you cannot find the lot number or if the label is faded, contact your pharmacy immediately with the bottle in hand; they can scan the barcode or look up the dispensing records to confirm the exact lot details.
What to do — step by step
If you currently have a bottle of Cinacalcet Hydrochloride Tablets manufactured by Cipla Ltd., the most important thing to remember is that the official recall announcement does not specify a particular remedy, such as a direct refund, repair, or replacement process. This absence of specific instructions can feel unsettling, but it does not mean you are left without guidance. In situations where the manufacturer has not outlined a specific return or exchange protocol, your primary focus should shift to immediate safety and proactive communication with your healthcare providers.
First, stop taking the medication immediately. Even though the hazard involves cGMP deviations regarding the presence of N-nitroso-cinacalcet above the acceptable daily intake, continuing to use the product is unnecessary risk when safer alternatives exist. Do not simply throw the bottle in your household trash, as this can sometimes lead to accidental ingestion by children or pets, or environmental contamination. Instead, keep the bottle sealed in its original packaging to preserve the lot numbers and expiration dates, which are critical for verification.
Second, contact your prescribing doctor or pharmacist right away. Since this is a prescription-only drug (Rx Only), you cannot simply switch to an over-the-counter alternative without medical supervision. Explain that you possess one of the recalled lots: 5PB0465, 5PB0466, 5PB0557, 5PB0629, 5PB0630, 5PB0633, or 5PB0637. Your healthcare provider can assess whether you need a new prescription from a different manufacturer or batch to ensure your treatment for hyperparathyroidism or related conditions continues without interruption. They may also advise you on any specific monitoring needed given the potential impurity.
Third, reach out to Cipla USA, Inc., the entity manufacturing for the U.S. market. While the recall notice does not list a dedicated hotline or return address in the text provided, you should attempt to contact them directly at their listed address: 10 Independence Boulevard, Suite 300, Warren, NJ 07059. Inquire about their current policy for handling recalled lots. They may have an internal process for collecting the product to ensure it does not re-enter the supply chain, or they may direct you to a third-party disposal service. Keep records of all calls and emails, including dates, names of representatives spoken to, and any reference numbers provided.
Finally, dispose of the medication safely if instructed to do so by your pharmacist or local waste authority. Many communities have drug take-back programs that accept medications without requiring a receipt or specific remedy from the manufacturer. If you cannot find a take-back location, mix the tablets with an unappealing substance like dirt, cat litter, or used coffee grounds in a sealed plastic bag before discarding them in your household trash, but only if local guidelines permit this method. The goal is to ensure the product is completely inaccessible to anyone who might accidentally use it.
Your refund, repair, or replacement options
When a medication is recalled due to manufacturing deviations, the primary concern is ensuring you do not consume a product that may not meet safety standards. In this specific case involving Cipla USA, Inc., the recall notice for Cinacalcet Hydrochloride Tablets does not explicitly outline a standardized consumer remedy such as a direct mail-in refund or an automated replacement program. This absence of stated terms is significant and requires a different approach than what you might expect from a typical retail return.
Because the official record does not provide specific instructions for refunds, repairs, or replacements, the process relies heavily on your relationship with the healthcare providers who prescribed or dispensed the medication. Typically, in pharmaceutical recalls where the manufacturer does not specify a consumer-facing remedy, the financial and logistical responsibility falls to the distribution chain. This means that if you purchased this medication from a pharmacy, that pharmacy is usually responsible for handling the return of the product and processing any associated credit or refund with their supplier or the distributor.
If you have unopened bottles of the recalled Cinacalcet Hydrochloride Tablets in your possession, the first and most critical step is to contact the pharmacy where you filled the prescription. Do not attempt to dispose of the medication in household trash or down the drain, as this can pose environmental risks. Instead, ask the pharmacist about their specific protocol for returning recalled pharmaceuticals. They will likely instruct you to bring the bottles back to the store. Once returned, they should void the charge on your insurance or credit card, effectively providing a refund or credit equivalent to what you originally paid.
If you are in the process of refilling a prescription and have not yet picked up the medication, inform your pharmacist immediately. They can check their inventory system against the recall lot numbers (5PB0465, 5PB0466, 5PB0557, 5PB0629, 5PB0630, 5PB0633, 5PB0637, and 5PB0638) to ensure you do not receive the affected units. In many cases, pharmacies will proactively quarantine these items before they reach the customer. If a replacement medication is needed due to the recall, your doctor may need to write a new prescription for an alternative product or a different manufacturer that is not part of this recall.
It is important to note that because the remedy is "not stated" in the official FDA notice, there is no central website or phone number provided specifically for consumers to request money back directly from Cipla USA, Inc. Therefore, your recourse is entirely through the point of sale. Keep your original receipt or prescription fill record handy when you contact the pharmacy, as this will expedite the verification process. If you have questions about the legal rights regarding the return, the FDA’s website or the manufacturer’s customer service line (if available) can provide general information, but they will likely direct you back to your pharmacy for financial resolution.
Always prioritize your health continuity during this process. Since Cinacalcet is used to treat conditions like hyperparathyroidism, do not stop taking your medication abruptly without consulting your doctor. While you wait for the recall resolution, your healthcare provider can help bridge any gaps in treatment with alternative therapies if necessary. The goal is to ensure that you are safely transitioned to a non-recalled product without interruption in your care.
What can happen if you ignore it
When a medication is recalled due to the presence of an impurity like N-nitroso-cinacalcet, the potential consequences of continuing to use that product are not merely theoretical; they are rooted in serious toxicological concerns. It is crucial to understand that this specific hazard involves a Class II recall by the FDA, which indicates a situation where use of the product could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. However, "remote" does not mean negligible, and ignoring the recall exposes you to risks that compound over time. N-nitroso compounds are widely recognized in medical science as potential carcinogens, meaning they have the capacity to cause cancer. The acceptable daily intake (ADI) established by regulatory bodies is a strict threshold designed to keep exposure levels as low as reasonably possible. When the concentration of N-nitroso-cinacalcet exceeds this ADI, you are effectively ingesting a level of impurity that has not been deemed safe for long-term human consumption. Cinacalcet itself is a potent medication used to treat conditions such as hyperparathyroidism and parathyroid carcinoma. Because it works by altering calcium levels in the blood, your body is already managing a delicate chemical balance. Introducing an unknown, potentially toxic variable into that system disrupts that balance not just in the moment of ingestion, but cumulatively over weeks or months of use. The real-world consequence of ignoring this recall is the accumulation of this impurity in your body. Unlike some contaminants that are flushed out quickly, certain nitroso compounds can persist or interact with cellular structures in ways that lead to DNA damage. While a single dose might not cause immediate, acute symptoms like nausea or dizziness, the danger lies in the silent, long-term risk. You might feel perfectly fine today, but the exposure continues to add up with every pill you take from the affected lots (5PB0465 through 5PB0638). This is particularly concerning because Cinacalcet is often taken as a maintenance therapy for chronic conditions, meaning patients may be exposed to this elevated risk for an extended period without realizing it. Furthermore, ignoring the recall creates a gap in your medical care. If you continue using contaminated tablets while waiting for a replacement or refund, you are not receiving the treatment you need in its proper form. This delay can lead to uncontrolled calcium levels, which can cause serious secondary health issues such as bone pain, kidney stones, or cardiac arrhythmias. The impurity does not treat your underlying condition; it only adds a layer of toxicity. By not acting, you are essentially gambling with your long-term cellular health for the sake of convenience, when a simple call to your pharmacy can resolve the issue safely and swiftly. The goal is to minimize any potential exposure immediately, ensuring that your body is not subjected to unnecessary carcinogenic risk while you manage your primary health condition.Staying safe: broader tips
While specific product recalls are necessary tools for maintaining public health, they represent a reactive measure rather than the primary line of defense against medication-related risks. The most effective way to stay safe with prescription drugs is to cultivate a proactive relationship with your healthcare providers and pharmacists. Always ask questions about new medications, particularly regarding potential impurities or manufacturing standards. If you have concerns about the source of your medication, do not hesitate to request that your pharmacist verify the manufacturer and lot number before filling the prescription. Building this habit ensures that you are aware of who is making your medicine and allows you to cross-reference information quickly if a recall announcement ever appears.
Regularly checking for safety alerts is another critical step in personal health management. The U.S. Food and Drug Administration (FDA) maintains a comprehensive database of drug recalls that is accessible to the public. Subscribing to FDA email updates or visiting their website periodically can help you stay informed about issues before they impact your daily routine. Similarly, many pharmaceutical manufacturers offer direct notification services for patients who purchase their products directly or through certain mail-order pharmacies. Signing up for these alerts provides an additional layer of security, ensuring that you receive information from multiple reliable sources.
Proper storage and handling of prescription medications also play a significant role in maintaining their integrity and safety. Most drugs require specific environmental conditions to remain effective and stable. Keep your medications in a cool, dry place away from direct sunlight, heat sources, and moisture, such as the inside of a bathroom cabinet rather than on the counter or in the shower. Avoid storing them in cars, where temperatures can fluctuate wildly. Always keep medications in their original containers with labels intact to prevent confusion and ensure you have access to important usage instructions and expiration dates.
Finally, maintain an organized inventory of your household medications. Periodically review what you have on hand and dispose of any expired or unused drugs properly. Many pharmacies and local law enforcement agencies offer drug take-back programs that provide a safe and environmentally responsible way to dispose of medicines. This practice not only reduces the risk of accidental ingestion by children or pets but also minimizes the potential for misuse. By staying informed, storing medications correctly, and keeping an eye on safety alerts, you take control of your health environment and reduce reliance on reactive measures like recalls.